Does liposomal bupivacaine reduce hospital length of stay for multilevel lumbar decompressions? A retrospective matched cohort study

• DOI: 10.25259/jmsr_108_2022
• Publication Date: 2022-11-08T09:50:55Z
• Authors: Abduljabbar Alham...; Houssam Bouloussa; Armen Oganesian; Isam S Moghamis; Calvin Kuo; Kamran Majid; Ravinder-Raj S. B...
• Keywords: Narcotic

Objectives: Adequate post-operative pain control improves patient outcomes, leading to fewer analgesia-related complications and shorter length of hospital stay (LOS). Liposomal bupivacaine (LB) is a long-acting injectable anesthetic. This study evaluates the impact local LB use on outcomes (LOS, visual analog scale [VAS], narcotic usage, readmission, complications) after multilevel spinal decompression surgery compared matched cohorts without LB. Methods: A single-center retrospective cohort by age, gender, body mass index (BMI), medical comorbidities, previous opioids was done at our institute. Subjects were divided into two groups; one who had end spine Patients’ demographics, number operating levels, parameters (LOS VAS), medications used preoperatively, through hospitalization discharge, complication rate, readmission rate collected. Results: Eighty-six patients with stenosis included; 45 (52.3%) in group 41 (47.7%) non-LB group. The average age 67.8 ± 10.5. Both groups comparable terms BMI comorbidities. There no diffidence killers consumption between groups, throughout discharge. Strong statistically significant difference VAS score favoring ( P < 0.001). LOS 15 h less (32.4 36.6 vs. 47.5 39.1) = 0.069). 10.6%, both 0.49). readmissions or emergency department visits for complaints. After excluding complications, significantly 0.029). In subgroup analysis look learning curve, less, second half included patients. However, did not reach statistical significance. Conclusion: LB, as infiltration lumbar decompression, an effective tool decrease shorten stay, especially complications.